Table of Content

Chapter 1: Market Demands for High Quality Equipment & Single Use Systems
Pipeline Growth in China, Market for mAb Therapeutics and Vaccines and Demand from Domestic Developers
Chapter 2: China’s Local Bioprocessing Equipment Competition Landscape
SWOT Analysis of China Domestic Vendors of Bioprocessing
Opportunities
Weaknesses
Threats
Chapter 3: Distribution of Bioprocessing Products in China
Why Western Vendors Should Use Distributors in China and How to Assess Chinese Distributors
Distribution Models in China
How to Manage Chinese Distributors
Chapter 4: Building a Relationship: Collaborations Between China Distributors and Western Vendors
How to Start Looking for A Chinese Distributor
What Types and How Many Distributors Should Be Hired
Questions to be Asked and Answered Before Hiring a Distributor in China
Priorities for a Western Manufacturer to Consider
Typical Distributor Commissions and Other Commitments
Process to Line up Distributor(s) in China
Legal and Other Reviews
Managing Distributors
Failure Case Studies
Case 1
Case 2
Successful Case Studies
Case 1
Case 2
Case 3
How to Build a Successful Relationship with Distributors in China
Chapter 5: Regulatory Environment and Reforms Impacting China Biologics Manufacturing
Drug Administration Law on Drug Manufacturing (2019)
Impact of Regulatory Environment for Domestic and Foreign Investors
Chapter 6: Top 60 Distributor Company Profiles



List of Figures


Fig 1: Services of a Biologics CMO
Fig 2: China Healthcare Total Expenditures and Growth Rates
Fig 3: Global Biologics Market
Fig 4: Market Size of mAb Therapeutics in China (2013-2030)
Fig 5: Growth in Biological Therapeutics Projects in China (2014-2018)
Fig 6: Revenue and Growth Rate of Avastin Before/After Listing in NRDL
Fig 7: Revenue and Growth Rate of Herceptin Before and After Listing in NRDL
Fig 8: Biologics Outsourcing Service Market Size
Fig 9: R&D Expenditures of Publicly Listed Biopharma Companies
Fig 10: China’s Progress in Innovation in Biologics
Fig 11: Cost Analysis of mAb Manufacture at Different Production Scales
Fig 12: BioPlan Survey Respondents’ Interests in Countries for Bioprocessing Outsourcing in 5 years, 2025
Fig 13: China’s Needs to Fill Gaps to Be an International Bioprocessing Hub
Fig 14: IND Applications to U.S. from Chinese Manufacturers
Fig 15: Therapeutic Products with INDs in U.S. and China
Fig 16: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations
Fig 17: Capacity Expansion Plans of WuXi Biologics
Fig 18A: Boehringer-Ingelheim’s Shanghai Facility
Fig 18B: Boehringer-Ingelheim’s Shanghai Facility
Fig 18C: Boehringer-Ingelheim’s Shanghai Facility
Fig 18D: Boehringer-Ingelheim’s Shanghai Facility
Fig 19: Manufacturing Capabilities
Fig 20A: CMAB Facility
Fig 20B: CMAB Facility
Fig 20C: CMAB Facility
Fig 21: MabPlex Facility
Fig 22: Titer under Fed Batch Culture
Fig 23: Titer of ChemPartner Biologics by Projects
Fig 24A: ChemPartner Facility
Fig 24B: ChemPartner Facility
Fig 24C: ChemPartner Facility
Fig 25: JOINN Facility
Fig 26A: Shanghai Biomabs Facility
Fig 26B: Shanghai Biomabs Facility
Fig 26C: Shanghai Biomabs Facility
Fig 26D: Shanghai Biomabs Facility
Fig 27: Services Provided by Shanghai Biomabs
Fig 28: OPM Culture Media Performance
Fig 29A: Yaohai Biopharma Facility
Fig 29B: Yaohai Biopharma Facility
Fig 29C: Yaohai Biopharma Facility
Fig 29D: Yaohai Biopharma Facility
Fig 29E: Yaohai Biopharma Facility
Fig 30A: Theramab Facility
Fig 30B: Theramab Facility
Fig 31: Asymchem Services in Biologics
Fig 32: Manufacturing Services of Asymchem
Fig 33: Asymchem Facilities
Fig 34: HJB Service Platform
Fig 35: HJB Facility
Fig 36A: Teruisi Pharma Facility
Fig 36B: Teruisi Pharma Facility

 

List of Tables


Table 1 mAbs from Domestic Developers Launched in China
Table 2 Partial List of mAbs in NRDL and Price Reduction
Table 3 Investment into the China Biologics CMOs in Recent Years
Table 4 MAH Impact on Domestic Developers
Table 5 Commercial Scale Bioproduction Deals in China
Table 6 mAbs from Domestic Developers Against IL-17/IL-23 Pathway Targets
Table 7 mAbs from Domestic Developers Against LAG-329
Table 8 Potential Market Value of Some mAb Targets in China
Table 9 Major Companies in China with Innovative Biologics Pipelines
Table 10 mAb Therapeutics Approved Last Year from Domestic Developers
Table 11 Current mAb Projects at Phase II/III from Chinese Developers
Table 12 Capacity Estimates for China CMO mAbs Manufacturing in 2020
Table 13 Domestic mAbs Capacity Needs for China-based CMOs in 2025
Table 14 China Market Size of Commercial Scale Contract Bioprocessing
Table 15 Current China-based CMO Capacity Estimates
Table 16 Expansion Plans of China-based Biopharmaceutical Developers in 2019-2020
Table 17 IND Applications for Biologics in both China and Western Countries
Table 18 Summary of Ratings by Interviewees of Importance of CMO Selection Criteria (on a 1-10 Scale) Table 19 WuXi’s Revenue Per Project Rises as Projects Mature